Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications
Cancer and cardiovascular disorders are known as the two main leading causes of mortality worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related chemotherapy. Chemotherapy-induced cardiotoxicity has been associated with various cancer treatments, such as anthracyclines,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223014841 |
| _version_ | 1797630677188870144 |
|---|---|
| author | Zahra Vaziri Kiarash Saleki Cena Aram Parsa Alijanizadeh Ramtin Pourahmad Abbas Azadmehr Naghmeh Ziaei |
| author_facet | Zahra Vaziri Kiarash Saleki Cena Aram Parsa Alijanizadeh Ramtin Pourahmad Abbas Azadmehr Naghmeh Ziaei |
| author_sort | Zahra Vaziri |
| collection | DOAJ |
| description | Cancer and cardiovascular disorders are known as the two main leading causes of mortality worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related chemotherapy. Chemotherapy-induced cardiotoxicity has been associated with various cancer treatments, such as anthracyclines, immune checkpoint inhibitors, and kinase inhibitors. Different methods have been reported for the management of chemotherapy-induced cardiotoxicity. In this regard, sodium-glucose cotransporter-2 inhibitors (SGLT2i), a class of antidiabetic agents, have recently been applied to manage heart failure patients. Further, SGLT2i drugs such as EMPA exert protective cardiac and systemic effects. Moreover, it can reduce inflammation through the mediation of major inflammatory components, such as Nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasomes, Adenosine 5'-monophosphate-activated protein kinase (AMPK), and c-Jun N-terminal kinase (JNK) pathways, Signal transducer and activator of transcription (STAT), and overall decreasing transcription of proinflammatory cytokines. The clinical outcome of EMPA administration is related to improving cardiovascular risk factors, including body weight, lipid profile, blood pressure, and arterial stiffness. Intriguingly, SGLT2 suppressors can regulate microglia-driven hyperinflammation affecting neurological and cardiovascular disorders. In this review, we discuss the protective effects of EMPA in chemotherapy-induced cardiotoxicity from molecular, immunological, and neuroimmunological aspects to preclinical and clinical outcomes. |
| first_indexed | 2024-03-11T11:10:33Z |
| format | Article |
| id | doaj.art-677017fb5cd24c7189098e7451e2a762 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-11T11:10:33Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-677017fb5cd24c7189098e7451e2a7622023-11-12T04:38:54ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-12-01168115686Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implicationsZahra Vaziri0Kiarash Saleki1Cena Aram2Parsa Alijanizadeh3Ramtin Pourahmad4Abbas Azadmehr5Naghmeh Ziaei6Student Research Committee, Babol University of Medical Sciences, Babol, Iran; USERN Office, Babol University of Medical Sciences, Babol, IranStudent Research Committee, Babol University of Medical Sciences, Babol, Iran; USERN Office, Babol University of Medical Sciences, Babol, Iran; Department of e-Learning, Virtual School of Medical Education and Management, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, IranDepartment of Cell & Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, IranStudent Research Committee, Babol University of Medical Sciences, Babol, Iran; USERN Office, Babol University of Medical Sciences, Babol, IranSchool of Medicine, Tehran University of Medical Sciences, Tehran, IranImmunology Department, Babol University of Medical Sciences, Babol, IranClinical Research Development unit of Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran; Department of Cardiology, Babol University of Medical Sciences, Babol, Iran; Corresponding author at: Department of Cardiology, Babol University of Medical Sciences, Babol, Iran.Cancer and cardiovascular disorders are known as the two main leading causes of mortality worldwide. Cardiotoxicity is a critical and common adverse effect of cancer-related chemotherapy. Chemotherapy-induced cardiotoxicity has been associated with various cancer treatments, such as anthracyclines, immune checkpoint inhibitors, and kinase inhibitors. Different methods have been reported for the management of chemotherapy-induced cardiotoxicity. In this regard, sodium-glucose cotransporter-2 inhibitors (SGLT2i), a class of antidiabetic agents, have recently been applied to manage heart failure patients. Further, SGLT2i drugs such as EMPA exert protective cardiac and systemic effects. Moreover, it can reduce inflammation through the mediation of major inflammatory components, such as Nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasomes, Adenosine 5'-monophosphate-activated protein kinase (AMPK), and c-Jun N-terminal kinase (JNK) pathways, Signal transducer and activator of transcription (STAT), and overall decreasing transcription of proinflammatory cytokines. The clinical outcome of EMPA administration is related to improving cardiovascular risk factors, including body weight, lipid profile, blood pressure, and arterial stiffness. Intriguingly, SGLT2 suppressors can regulate microglia-driven hyperinflammation affecting neurological and cardiovascular disorders. In this review, we discuss the protective effects of EMPA in chemotherapy-induced cardiotoxicity from molecular, immunological, and neuroimmunological aspects to preclinical and clinical outcomes.http://www.sciencedirect.com/science/article/pii/S0753332223014841SGLT2iEMPAChemotherapyCardiotoxicityHeart failure |
| spellingShingle | Zahra Vaziri Kiarash Saleki Cena Aram Parsa Alijanizadeh Ramtin Pourahmad Abbas Azadmehr Naghmeh Ziaei Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications Biomedicine & Pharmacotherapy SGLT2i EMPA Chemotherapy Cardiotoxicity Heart failure |
| title | Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications |
| title_full | Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications |
| title_fullStr | Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications |
| title_full_unstemmed | Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications |
| title_short | Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications |
| title_sort | empagliflozin treatment of cardiotoxicity a comprehensive review of clinical immunobiological neuroimmune and therapeutic implications |
| topic | SGLT2i EMPA Chemotherapy Cardiotoxicity Heart failure |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223014841 |
| work_keys_str_mv | AT zahravaziri empagliflozintreatmentofcardiotoxicityacomprehensivereviewofclinicalimmunobiologicalneuroimmuneandtherapeuticimplications AT kiarashsaleki empagliflozintreatmentofcardiotoxicityacomprehensivereviewofclinicalimmunobiologicalneuroimmuneandtherapeuticimplications AT cenaaram empagliflozintreatmentofcardiotoxicityacomprehensivereviewofclinicalimmunobiologicalneuroimmuneandtherapeuticimplications AT parsaalijanizadeh empagliflozintreatmentofcardiotoxicityacomprehensivereviewofclinicalimmunobiologicalneuroimmuneandtherapeuticimplications AT ramtinpourahmad empagliflozintreatmentofcardiotoxicityacomprehensivereviewofclinicalimmunobiologicalneuroimmuneandtherapeuticimplications AT abbasazadmehr empagliflozintreatmentofcardiotoxicityacomprehensivereviewofclinicalimmunobiologicalneuroimmuneandtherapeuticimplications AT naghmehziaei empagliflozintreatmentofcardiotoxicityacomprehensivereviewofclinicalimmunobiologicalneuroimmuneandtherapeuticimplications |